Bivalirudin Drug Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 - 2028

  • Single User License $3500

Bivalirudin Drug Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 - 2028

Status : May, 2021 | Pharmaceutical

Report Digest

Bivalirudin Drug Market Introduction

Bivalirudin is a synthetic residue peptide and it is direct thrombin inhibitor (DTI). It is an anticoagulant that helps to prevent the formation of blood clots, especially in people with severe chest pain or ones who are undergoing angioplasty. Bivalirudin is for IV use only and it is supplied as a sterile, lyophilized product, and glass vials. Moreover, Bivalirudin is also used conjuction with other medicines.

Bivalirudin drugs are finding wide application in patients undergoing Percutaneous Transluminal Coronary Angioplasty (PTCA) and percutaneous coronary intervention (PCI) procedures. Bivalirudin is not given to patients with active major bleeding. The most common adverse health effects of Bivalirudin are pain, nausea, back pain, hypotension, and headache. Meanwhile, Bivalirudin is also approved for cardiac patients undergoing PCI. Bivalirudin is also partly cleared by renal mechanism, hence, the dose administration needs to be managed for patients with severe renal impairment.

Bivalirudin Drug Market: Notable Developments

  • Accord Healthcare has entered into the license agreement with Foresee Pharma. Under the agreement, Foresee will receive combination of regulatory, sales and upfront milestone, in addition to the significant share of the product revenue as Accord Healthcare will cover overall cost of commercialization in the global market with exception of Japan, mainland China, the US, and Taiwan, along with previously partnered territories including various countries in the Middle East, Turkey, and Israel.
  • Aurobindo Pharma has acquired Apotex’s commercial operations in five European countries including the Netherlands, Belgium, Poland, Spain, and the Czech Republic.
  • Beximo Pharmaceuticals Limited plans to buy eight ANDAs in the US from Sandoz Inc., a division of Novartis. Following this deal, Beximo Pharma will have 14 approved ANDAs in its product portfolio in the US.

Some of the most prominent competitors operating in the competitive landscape of global bivalirudin drug market include –

  • Sandoz
  • Dr. Reddys Laboratories
  • Fresenius Kabi
  • Apotex
  • The Medicines Company
  • Pfizer
  • Aurobindo Pharma
  • Mylan
  • Accord Healthcare
  • Sun Pharmaceuticals Industries Limited
  • Ferring Pharmaceuticals

Bivalirudin Drug Market Dynamics

Bivalirudin Drug as Alternative to Heparin for Anticoagulation in Children and Infants

Bivalirudin has emerged as an alternative for heparin for infants and children in anticoagulation. Moreover, Bivalirudin, unlike heparin, does not require antithrombin to be effective, thus providing more consistent anticoagulation. The use of DTI among children and infants has been uncommon. However, the primary reason for use of DTI is the development of thrombus or HIT extension during the heparin therapy.

Although the use of Bivalirudin is not common in pediatrics, the use of DTI is slowly increasing owing to the rise in diagnosis of HIT. Meanwhile, in various studies, researchers have found a significant reduction in the rate of bleeding after using DTI with Bivalirudin as compared to argatroban. Meanwhile, the first pilot study on use of Bivalirudin to treat thrombosis in infants was presented in 2007. After this more research has been done resulting in the successful use of Bivalirudin in various cases including children undergoing cardiac catheterization.

Increasing Use of Bivalirudin Drug in Patients Undergoing PCI

The acute coronary syndrome is emerging as the most common cause of death globally. This is driving the demand for Percutaneous Coronary Intervention (PCI) to manage acute coronary syndrome. In order to reduce the risk of thrombotic complications, the use of anticoagulation therapy is increasing during PCI, thereby, driving the demand for Bivalirudin drug as the anticoagulant drug as it reduces the risk of bleeding during the procedure. Moreover, Bivalirudin drug has also been licensed as an alternative to Heparin for the patients undergoing PCI and also for the patients with HIT who go for PCI.

The sale of Bivalirudin drug is also increasing as anticoagulant drug owing to the advantages as compared to similar drugs in the market. Moreover, Bivalirudin does not present complications including hemorrhagic and ischemic that are often caused by other anticoagulant drugs.

High Cost of Bivalirudin Drug to Restrain its Growth

Despite increasing use of Bivalirudin drug as a substitute for Heparin and other anticoagulant drugs, the high cost of Bivalirudin drug is restricting its use among patients with low or moderate risk of bleeding. Although, Bivalirudin has shown better results in patients undergoing PCI, its high cost may restrict its use among patients. Moreover, expenditure review by various healthcare institutions have also noted a significant increase in the contribution of Bivalirudin drug on the overall drug budget.

Various organizations and governments are focusing on cost saving initiatives to reduce the cost of Bivalirudin and also reduce its wastage by providing the dosage as required depending on the patient’s condition.

Bivalirudin Drug Market Segmentation

Based on the types, the Bivalirudin drug market is segmented into

  • Ready-to-use solution
  • Powder for reconstitution

On the basis of application, the Bivalirudin drug market is segmented into

  • Drug store
  • Hospital

By end use the Bivalirudin drug market is segmented into

  • Percutaneous Coronary Intervention (PCI) Procedures
  • Percutaneous Transluminal Coronary Angioplasty (PTCA) Procedures
  • Others

This study provides a particularized anatomy according to the L.E.A.P mechanism

  • Latest trends and cardinal growth prospects
  • Existing and future insights in growth
  • Ascensions in technology
  • Pain points

The regional analysis offers market assays across:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The study, prepared through the L.E.A.P mechanism adds a dimension of infallibility and assures precise information on all the growth dynamics.

Latest Trends and Cardinal Growth Prospects

The study assists in burnishing the knowledge of the stakeholder in terms of the emerging trends. The study provides an expansive coverage on the latest developments and novel profit-yielding sources that augur well with the market. A dedicated and determined team of experts conduct an out-and-out research on diverse aspects to offer ultimate breakthroughs in the market.

Existing and Future Insights in Growth

The interfusion of ubiquitous primary and secondary research through modern tools invites perfection and accuracy in every aspect. Primary research is circumspectly conducted through exhaustive interactions and interviews of experts. These valuable opinions are then neatly inducted in the report to allow the stakeholder for reaping the benefits. A treasure of secondary data is extracted via famed paid sources, yearly estimates and statements, renowned journals, and government documents. These sources assist in creating a robust database comprising existing and subsequent growth dynamics.

Ascensions in Technology

Diverse technological advancements and cutting-edge innovations in the market have been covered in this study to assist the stakeholder in research and development activities. Recent upgrades have also been added in the study, thus helping the stakeholder to paint the strokes of growth on the canvas of the market.

Pain Points

The study presents a plethora of challenges and obstacles that can hinder the growth of the market to allow the stakeholder to prepare their strategies accordingly.

The world ushered in the new decade with the shadow of the COVID-19 pandemic. The outbreak has damaged the growth prospects of several businesses and has crippled the entire economy. The study is in tandem with the changing dynamics of the market due to the SARS-CoV-2 outbreak. The study focuses on the coronavirus pandemic and analyses every aspect that impacts the growth positively or negatively.

An aerial perspective of the regions covered in this study enables the stakeholder to design strategies accordingly. The 360-degree assessment of every aspect associated with growth offers information on a rainbow of growth opportunities available across the market.

The exhaustive study motivates the stakeholder to take the 'LEAP' of faith and achieve success!

This report is the key to questions such as:

What are the prominent factors that will help in reshaping the market growth?

Which trends have the potential to bring expansive growth for the market?

What are the necessary strategies to overcome the ill-effects of the COVID-19 pandemic?

Which regions will emerge as champion growth contributors for the market?

Which aspects will serve as game-changers for the market?

What are the latest innovations in the market?

Which factors will hinder the growth of the market?